Pluri Inc News - PLUR

Professional-Grade Tools, for Individual Investors.

Premium

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment

Placental Mucosal Associated Invariant T (MAIT) cells are unique unconventional immune T cells which are...

Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method

Pluri’s patent enables mass-scale production of immune cell therapiesNew patented technology is applicable for...

Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences

HAIFA, Israel, March 28, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the...

Pluri Inc. Announces 1-for-8 Reverse Share Split

HAIFA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the...

Pluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report

International Coffee Organization (ICO) Market Report published on March 7, 2024 highlights alarming price...

👍️ 1

FDApproved 2 days ago

November Company Presentation !!!

https://pluri-biotech.com/presentation/

👍️ 1

FDApproved 4 days ago

Placenta-Derived Mesenchymal Stromal-Like Cells Promote 3D-Engineered Muscle Tissue Differentiation and Vessel Network Maturation

https://onlinelibrary.wiley.com/doi/10.1002/smsc.202470045

👍️ 2

FDApproved 5 days ago

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

https://finance.yahoo.com/news/brainstorm-cell-therapeutics-pluri-partner-110000497.html

👍️ 2

sekander 1 week ago

The whole stock market's on fire with the Trump election but this piece of manure
can't push open its coffin lid.

👍️0

FDApproved 1 week ago

Healthy Aging/Longevity Company Coming From Pluri Biotech Soon !!!

Future Spin-Offs !!!

1. Ever After Foods
2. Coffeesai
3. Human Longevity

👍️ 1

FDApproved 2 weeks ago

Can a Placenta Cure Cancer ?

https://www.biu.ac.il/en/article/582414

👍️ 1

FDApproved 2 weeks ago

Pluri, BIRAD bring tumor-fighting MAIT cells to commercial viability

https://www.bioprocessintl.com/deal-making/pluri-birad-bring-tumor-fighting-mait-cells-to-commercial-viability

👍️ 1

FDApproved 2 weeks ago

4 Undervalued Hidden Gems With True Growth Potential

https://www.investing.com/analysis/4-undervalued-hidden-gems-with-true-growth-potential-200653457

👍️ 2

FDApproved 3 weeks ago

New Company Presentation !!!

https://pluri-biotech.com/presentation/

👍️ 1

FDApproved 3 weeks ago

https://www.contractpharma.com/contents/view_breaking-news/2024-10-28/pluri-and-bar-ilan-university-partner-to-advance-mait-cell-therapy-for-solid-tumors/

👍️ 1

FDApproved 3 weeks ago

Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells

https://pubmed.ncbi.nlm.nih.gov/39037052/

👍️ 1

FDApproved 3 weeks ago

Under this collaboration, Prof. Cohen’s novel Siglec-based Chimeric Switch Receptors (“CCR”) will be integrated into Pluri’s CAR-MAIT cell therapy platform to significantly enhance CAR-MAIT’s efficacy and tumor specificity.

👍️ 1

FDApproved 3 weeks ago

Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority

https://pluri-biotech.com/releases/pluri-collaborates-with-bar-ilan-university-to-advance-cancer-immunotherapy-for-solid-tumors-supported-by-israel-innovation-authority/

👍️ 1

FDApproved 3 weeks ago

Overcoming Scalability Barriers To Advance Cell Therapies in Development: CDMOs Can Be the Key to Success

https://www.bioprocessintl.com/cell-therapies/overcoming-scalability-barriers-to-advance-cell-therapies-in-development-cdmos-can-be-the-key-to-success

👍️ 1

FDApproved 4 weeks ago

HealthTechShaping the Future of Longevity With Yaky Yanay And James “Jim” Roosevelt from Pluri : How Pluri’s Therapies Are Shaping the Future of Aging and Healthcare

https://techbullion.com/shaping-the-future-of-longevity-with-yaky-yanay-and-james-jim-roosevelt-from-pluri-how-pluris-therapies-are-shaping-the-future-of-aging-and-healthcare/

👍️ 1

FDApproved 1 month ago

Interview with Lior Raviv, Chief Technology Officer at Pluri

https://techbullion.com/3d-cell-expansion-technology-revolutionizing-industries-interview-with-lior-raviv-chief-technology-officer-at-pluri/

👍️ 1

FDApproved 2 months ago

Pluri.......IS ALL SET WITH NASDAQ COMPLIANCE !!!

GIDDY-UP !!!

On September 26, 2024, the Company received a letter from Nasdaq, determining that the Company has regained compliance and that the matter is now closed.

https://www.sec.gov/ix?doc=/Archives/edgar/data/1158780/000121390024083652/ea0216191-8k_pluri.htm

👍️ 2

FDApproved 2 months ago

Imagine Being As Clueless As Scotty And Not Owning Lots Of Pluri !

Man, He Sure Is As Clueless As They Come !!!

👍️ 1

FDApproved 2 months ago

Good Read !!!

https://www.contractpharma.com/issues/2024-09-01/view_features/cdmo-specialization/?widget=listSection

👍️ 1

Scott999 2 months ago

Imagine being the CEO of a pos company that has blown through $420,000,000.00 and has got $320k in revenue for the year. I’m sure his $741k compensation for 2023. That’s on top of his $2.9 million compensation for 2023. Amazing that these guys aren’t in jail.

How that cdmo revenue do? Laughable just like the clowns. Where’s Zzatt boy when you need him? We got Zzientists. We got Zzientists

👍️ 1

FDApproved 2 months ago

WOW !!!

https://podcast.jesslarsen.net/yaky-yanay/

👍️ 1

FDApproved 2 months ago

Nice....Pluri Biotech- United States Patent For Non-Diabetic CLI & IC Patients
Which Is 20 to 40 % of ALL CLI Patients !!!

Note: The Patent Also Has A Digital App For Patients & Providers !!! Awesome !!!

https://patentscope.wipo.int/search/en/detail.jsf?docId=US438195758&_cid=P11-M0V2TK-99057-1

👍️ 1

FDApproved 2 months ago

September Company Presentation:

https://pluri-biotech.com/presentation/

👍️ 1

FDApproved 2 months ago

The Future of Cell-Based Products with Yaky Yanay, CEO of Pluri

👍️ 1

FDApproved 3 months ago

August 27th

https://industrializingcultivatedmeats.com/expert-speakers/

👍️ 1

FDApproved 3 months ago

Believer Meats Study is “First” Demonstration of Cost-Efficient Manufacturing of Cultivated Meat

https://cultivated-x.com/meat/study-continuous-manufacturing-cultivated-meat-significantly-reduce-costs/

👍️ 1

FDApproved 3 months ago

Yaky Yanay, Pluri President & CEO will be presenting the Pluri story at 10.30am ET virtually on August 20, 2024.

Register To View Webcast

https://www.webcaster4.com/Webcast/Page/3062/51171

👍️ 1

FDApproved 3 months ago

Stirring the pot: Bioreactor breakthroughs

https://www.thecellbase.com/news/stirring-the-pot-bioreactor-breakthroughs

👍️ 1

FDApproved 3 months ago

New Tutes !!!

August 14th-UBS-- 10,167 Shares
August 15th-Jane Street-- 8,396 Share

👍️ 1

FDApproved 3 months ago

Coffee Without Beans !!!

https://vegconomist.com/plant-cell-cultivation/companies-making-plants-cells/

👍️ 1

FDApproved 3 months ago

Food Business News

https://www.foodbusinessnews.net/articles/26608-ever-after-foods-receives-10-million-investment

👍️ 1

FDApproved 3 months ago

Nice !!!

https://industrializingcultivatedmeats.com/speaker/barak-zohar/

👍️ 1

FDApproved 3 months ago

WOW !!!

https://ccr.cancer.gov/news/milestones-2024/an-unexpected-cancer-killer

👍️ 1

FDApproved 3 months ago

Abstract: Placental-derived stromal-like cells (PLX-PAD) have been shown to facilitate muscle tissue recovery after injury and stimulate angiogenesis.

https://onlinelibrary.wiley.com/doi/full/10.1002/smsc.202400228

👍️ 1

FDApproved 4 months ago

Kadimastem taps Pluri to produce therapeutic cells for ALS and diabetes

https://www.bioprocessintl.com/deal-making/kadimastem-taps-pluri-to-produce-therapeutic-cells-for-als-and-diabetes

👍️ 1

FDApproved 4 months ago

Pluri’s CDMO arm takes on ALS and diabetes in cell therapy deal

https://www.biopharma-reporter.com/Article/2024/07/23/Pluri-CDMO-lands-ALS-and-diabetes-cell-therapy-deal?int_campaign=Related-News&int_campaign_type=Right_column

👍️ 1

FDApproved 4 months ago

Pluri’s CDMO to Manufacture Kadimastem’s Cell Therapy Candidates

https://www.contractpharma.com/contents/view_breaking-news/2024-07-18/pluris-cdmo-to-manufacture-kadimastems-cell-therapy-candidates/

👍️ 1

FDApproved 4 months ago

Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates

https://pluri-biotech.com/releases/pluris-cdmo-selected-to-manufacture-kadimastems-novel-cell-therapy-product-candidates/

👍️ 1

FDApproved 4 months ago

“By combining advanced cell expansion technology with the unique attributes of MAIT cells, Pluri is on the brink of delivering off-the-shelf solutions with unmatched consistency,” said Dr. Richard L. Kendall.

Dr. Kendall, Ph.D, is Chief Science Officer of Catena Bio, a company whose technology enables them to synthesize novel biomolecules in any structure, combination, or orientation. Previously, Dr. Kendall was the President and CEO of ImmPACT BIO, a cell therapy company developing engineered T cells for the treatment of cancer. Notably, Dr. Kendall also held significant positions at leading biopharmaceutical companies, serving as Vice President of Research at Kite Pharma, where he was responsible for the company’s research pipeline and development of CAR-T technologies, as well as Executive Director and Head of Oncology Research at Amgen.

https://drug-dev.com/pluri-launches-novel-immunotherapy-platform-for-solid-tumor-treatment/

👍️ 2

FDApproved 4 months ago

If Pluri's CAR-Mait Cells Are Able To Treat Solid Tumors? It Will Become One Of The Most Important Advances In The History of Oncology !!!

👍️ 2

FDApproved 4 months ago

Off the Shelf Platform: Efrat Kaduri from Pluri Inc. In a Riveting Conversation with PharmaShots

https://www.pharmashots.com/18344/off-the-shelf-platform-efrat-kaduri-from-pluri-inc-in-a-riveting-conversation-with-pharmashots

👍️ 2

FDApproved 4 months ago

July Company Presentation:

https://pluri-biotech.com/wp-content/uploads/2024/07/Pluri-PPT-investor_Q2_July_2024-final.pdf

👍️ 2

FDApproved 4 months ago

https://pluri-biotech.com/releases/pluri-announces-e1-million-proof-of-concept-agreement-to-enhance-global-sustainable-vegetable-supply/

👍️ 2

FDApproved 4 months ago

Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply

https://www.streetinsider.com/Globe+Newswire/Pluri+Announces+%E2%82%AC1+Million+Proof+of+Concept+Agreement+to+Enhance+Global+Sustainable+Vegetable+Supply/23438713.html

👍️ 2

Monksdream 4 months ago

PLUR under $10

👍️0

FDApproved 5 months ago

"Don’t write off cultivated meat just yet, says Ever After Foods: ‘We’re not offering incremental improvements but something truly disruptive."

https://agfundernews.com/dont-write-off-cultivated-meat-just-yet-says-ever-after-foods-were-not-offering-incremental-improvements-but-something-truly-disruptive

👍️ 1

FDApproved 5 months ago

WOW !!!

https://agfundernews.com/dont-write-off-cultivated-meat-just-yet-says-ever-after-foods-were-not-offering-incremental-improvements-but-something-truly-disruptive

👍️ 1

FDApproved 5 months ago

Dr. Michal Sheleg on a Novel Immunotherapy Platform for Solid Tumor Treatment

https://docwirenews.com/post/dr-michal-sheleg-on-a-novel-immunotherapy-platform-for-solid-tumor-treatment

👍️ 2

FDApproved 5 months ago

New Immune Cell Patent !!!

IMO...PLURI BIOTECH WILL DOMINATE THE GLOBAL IMMUNE CELL EXPANSION MARKET !!!

Expanded To Many Types Of Immune Cells !!

Immune cells are one of Jurkat, T2 cells, K562 cells, Raji, U973, THP-1, HL-60, Peripheral Blood Mononuclear Cells (PBMC), polymorphonuclear cells (PMN), conventional and unconventional T cells, B cells, B cell Hybridomas, CAR-B, NKT cells, CAR-NKT, gamma-delta T (gdT), CAR-gdT, NK cells, CAR-NK, and combinations thereof. Said conventional or unconventional T-Cell immune cells are unmodified or modified T cells consisting of the group: CAR-T, CAR-MAIT, modified T cell receptor (TCR)-T, modified TCR-MAIT, TILs (Tumor Infiltrating Lymphocytes), and combinations thereof.

The method according to claim 18, further comprising a step of genetically modifying said population of immune cells inside said 3D bioreactor by adding to said fluid media one or more gene modifying agents capable of genetically modifying said population of immune cells suspended in said fluid media spiked into said fluid media.

https://patentscope.wipo.int/search/en/detail.jsf?docId=US431346161&_cid=P12-LXQ3ZQ-63878-1

👍️ 2

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Pluri Inc (PLUR)

Professional-Grade Tools, for Individual Investors.

PLUR News

Form S-8 - Securities to be offered to employees in employee benefit plans

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment

Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method

Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences

Pluri Inc. Announces 1-for-8 Reverse Share Split

Pluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report

Engage with Pluri's Talent: Exciting Conference Appearances Ahead

Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing

Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals

Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individuals

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

PLUR Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Pluri Inc (PLUR) News

Pluri Inc (PLUR)

Professional-Grade Tools, for Individual Investors.

PLUR News

Form S-8 - Securities to be offered to employees in employee benefit plans

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment

Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method

Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences

Pluri Inc. Announces 1-for-8 Reverse Share Split

Pluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report

Engage with Pluri's Talent: Exciting Conference Appearances Ahead

Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing

Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals

Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individuals

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

PLUR Discussion

Your Recent History

Company

Business

Popular

Get The App